- Home
- BB vs RCUS Comparison
BB vs RCUS Comparison
Compare BB & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BB | RCUS |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.8B |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BB | RCUS |
|---|---|---|
| Price | $7.64 | $29.66 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $4.85 | ★ $31.90 |
| AVG Volume (30 Days) | ★ 9.3M | 1.2M |
| Earning Date | 04-09-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 169.23 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $549,100,000.00 | $247,000,000.00 |
| Revenue This Year | $12.21 | N/A |
| Revenue Next Year | $8.95 | $45.62 |
| P/E Ratio | $87.00 | ★ N/A |
| Revenue Growth | ★ 2.65 | N/A |
| 52 Week Low | $3.12 | $11.28 |
| 52 Week High | $13.59 | $31.74 |
Technical Indicators
Market Signals| Indicator | BB | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 52.08 |
| Support Level | $7.67 | $25.94 |
| Resistance Level | $9.34 | $31.47 |
| Average True Range (ATR) | 0.35 | 1.28 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 5.56 | 46.81 |
Price Performance
Historical ComparisonAbout BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.